20/04/2020
Label.BlogRelatedPostsText
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA set to expand Specialty portfolio with positive CHMP opinion on Kinpeygo orphan medicine for IgAN kidney disease
STADA has taken a significant step towards expanding its Specialty portfolio
STADA responds to urgent need by making more medicines
March 2020 saw the highest production output in STADA’s 125-year history as the COVID-19 crisis significantly raised demand for critical medicines.